High frequency of BRAF mutations in nevi
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
To evaluate the timing of mutations in BRAF (v-raf murine sarcoma viral oncogene homolog B1) during melanocytic neoplasia, we carried out mutation analysis on microdissected melanoma and nevi samples. We observed mutations resulting in the V599E amino-acid substitution in 41 of 60 (68%) melanoma metastases, 4 of 5 (80%) primary melanomas and, unexpectedly, in 63 of 77 (82%) nevi. These data suggest that mutational activation of the RAS/RAF/MAPK pathway in nevi is a critical step in the initiation of melanocytic neoplasia but alone is insufficient for melanoma tumorigenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, the BRAF oncogenic mutation found in more than half of all malignant cutaneous melanomas is commonly found also in non-malignant nevi, where it causes oncogene-induced senescence exemplified by high levels of CDKN2A and SA-β-gal expression225–227.”
From SenNet recommendations for detecting senescent cells in different tissues (2024) · cites this paper as [226]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Tissue microarrays for high-throughput molecular profiling of tumor specimens
Kononen, J., Bubendorf, L., Kallionimeni, A., Bärlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,099
Busca, R. (2000) · The EMBO Journal · doi:10.1093/emboj/19.12.2900 · Cited by 326
The Regulation of Normal Melanocyte Proliferation
Halaban, R. (2000) · Pigment Cell Research · doi:10.1034/j.1600-0749.2000.130103.x · Cited by 179
Research works printed but not linked: 2
- Armstrong, B.K. & English, D.R. in Cancer Epidemiology and Prevention (Oxford University Press, New York, 1996).
- Elder, D.E. & Murphy, G.F. in Atlas of Tumor Pathology: Melanocytic Tumors of the Skin 5–101 (Armed Forces Insititute of Pathology, Washington, DC, 1991).
Cited by
Items 101–200 of 1,001
Meier, F. (2005) · Frontiers in Bioscience · doi:10.2741/1755 · Cited by 267
“2989 nevi (13) suggesting that B-Raf mutation is an early but not sufficient event in malignant melanocyte transformation.”
BackgroundMcConnell, M. J., Moran, J. V., Abyzov, A., Akbarian, S., Bae, T., Cortes-Ciriano, I., Erwin, J. A., Fasching, L., Flasch, D. A., Freed, D., et al. (2017) · Science · doi:10.1126/science.aal1641 · Cited by 262
Platz, A., Egyhazi, S., Ringborg, U., & Hansson, J. (2008) · Molecular Oncology · doi:10.1016/j.molonc.2007.12.003 · Cited by 260
Cellular senescence in vivo: a barrier to tumorigenesis
Prieur, A., & Peeper, D. S. (2008) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.01.007 · Cited by 260
Imperfect wound healing sets the stage for chronic diseases
Martin, P., Pardo-Pastor, C., Jenkins, R. G., & Rosenblatt, J. (2024) · Science · doi:10.1126/science.adp2974 · Cited by 244
Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis
Vredeveld, L. C. W., Possik, P. A., Smit, M. A., Meissl, K., Michaloglou, C., Horlings, H. M., Ajouaou, A., Kortman, P. C., Dankort, D., McMahon, M., et al. (2012) · Genes & Development · doi:10.1101/gad.187252.112 · Cited by 262
“The primary molecular engine driving melanomagenesis is the activation of the ERK pathway, mainly due to oncogenic mutation of BRAF (Davies et al. 2002; Pollock et al. 2003) or NRAS (Raybaud et al. 1988; van’t Veer et al. 1989).”
BackgroundInfluentialElucidating Distinct Roles for NF1 in Melanomagenesis
Maertens, O., Johnson, B., Hollstein, P., Frederick, D. T., Cooper, Z. A., Messiaen, L., Bronson, R. T., McMahon, M., Granter, S., Flaherty, K., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0313 · Cited by 258
“Analysis of human lesions and mouse models has demonstrated that BRAF mutations drive the development of benign nevi (14-16).”
BackgroundToward a Molecular Classification of Melanoma
Fecher, L. A., Cummings, S. D., Keefe, M. J., & Alani, R. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0442 · Cited by 252
Melanoma in congenital melanocytic naevi
Kinsler, V. A., O'Hare, P., Bulstrode, N., Calonje, J. E., Chong, W. K., Hargrave, D., Jacques, T., Lomas, D., Sebire, N. J., & Slater, O. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15301 · Cited by 248
Melanocytic nevi and melanoma: unraveling a complex relationship
Damsky, W. E., & Bosenberg, M. (2017) · Oncogene · doi:10.1038/onc.2017.189 · Cited by 248
Fecher, L. A., Amaravadi, R. K., & Flaherty, K. T. (2008) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3282f5271c · Cited by 249
Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma
Davies, M. A., Stemke-Hale, K., Lin, E., Tellez, C., Deng, W., Gopal, Y. N., Woodman, S. E., Calderone, T. C., Ju, Z., Lazar, A. J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1985 · Cited by 252
“For example, although benign nevi have no malignant potential, they harbor BRAF mutations at a rate similar to melanomas (7, 8).”
BackgroundUltraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53
Viros, A., Sanchez-Laorden, B., Pedersen, M., Furney, S. J., Rae, J., Hogan, K., Ejiama, S., Girotti, M. R., Cook, M., Dhomen, N., et al. (2014) · Nature · doi:10.1038/nature13298 · Cited by 249
“Furthermore, the incidence of acquired human naevi, ~80% of which carry BRAF mutations 9 , is linked to UVR exposure 10 .”
BRAF-KIAA1549 Fusion Predicts Better Clinical Outcome in Pediatric Low-Grade Astrocytoma
Hawkins, C., Walker, E., Mohamed, N., Zhang, C., Jacob, K., Shirinian, M., Alon, N., Kahn, D., Fried, I., Scheinemann, K., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0034 · Cited by 250
Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma
Devitt, B., Liu, W., Salemi, R., Wolfe, R., Kelly, J., Tzen, C., Dobrovic, A., & McArthur, G. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00873.x · Cited by 246
“All primary melanomas were screened with duplex allele-specific PCRs for the BRAFV600E mutation using primer design and PCR conditions as outlined by Pollock et al. (2003).”
MethodMolecular Markers and Targets in Melanoma
Teixido, C., Castillo, P., Martinez-Vila, C., Arance, A., & Alos, L. (2021) · Cells · doi:10.3390/cells10092320 · Cited by 219
“e presence of BRAF mutations in evi supports the ypothesis that activation of the RAF/MEK/ pathway is an e rly event in melanoma development [47].”
BackgroundClinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma
Ellerhorst, J. A., Greene, V. R., Ekmekcioglu, S., Warneke, C. L., Johnson, M. M., Cooke, C. P., Wang, L.-E., Prieto, V. G., Gershenwald, J. E., Wei, Q., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2276 · Cited by 243
“Adding to the debate surrounding the clinical relevance of BRAF mutations in primary melanoma is the observation that these mutations occur in benign nevi at a similar or greater frequency (11).”
BackgroundBRAF and NRAS mutations in melanoma and melanocytic nevi
Poynter, J. N., Elder, J. T., Fullen, D. R., Nair, R. P., Soengas, M. S., Johnson, T. M., Redman, B., Thomas, N. E., & Gruber, S. B. (2006) · Melanoma Research · doi:10.1097/01.cmr.0000222600.73179.f3 · Cited by 245
Rahmani, M., Davis, E. M., Crabtree, T. R., Habibi, J. R., Nguyen, T. K., Dent, P., & Grant, S. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01080-06 · Cited by 241
“The discovery that aberrant activation of the Ras-RafMEK1/2-ERK1/2 module occurs in a high percentage (30%) of human cancers (12, 42, 48, 57) provided a rationale for attempting to disrupt this pathway as a candidate anticancer strategy.”
BackgroundThe Role of the PI3K-AKT Pathway in Melanoma
Davies, M. A. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e31824d448c · Cited by 240
“Both activating BRAF and NRAS mutations are found at high rates in benign nevi, which have very little malignant potential.(3,4) Similarly, expression of activated BRAF alone fails to transform benign melanocytes.”
BackgroundSkin cancer biology and barriers to treatment: Recent applications of polymeric micro/nanostructures
Khan, N. H., Mir, M., Qian, L., Baloch, M., Ali Khan, M. F., Rehman, A.-U., Ngowi, E. E., Wu, D.-D., & Ji, X.-Y. (2022) · Journal of Advanced Research · doi:10.1016/j.jare.2021.06.014 · Cited by 234
MicroRNA-193b Represses Cell Proliferation and Regulates Cyclin D1 in Melanoma
Chen, J., Feilotter, H. E., Paré, G. C., Zhang, X., Pemberton, J. G. W., Garady, C., Lai, D., Yang, X., & Tron, V. A. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.091061 · Cited by 238
“Interestingly, more than 80% of benign nevi, which rarely progress to melanoma, also harbor Braf mutations.(32) It is hypothesized that these melanocytes fail to proliferate and progress because of oncogene-induced cell senescence and that additional mutations are needed for complete Figure 6.”
BackgroundIn ovarian neoplasms, BRAF , but not KRAS , mutations are restricted to low‐grade serous tumours
Sieben, N. L., Macropoulos, P., Roemen, G. M., Kolkman‐Uljee, S. M., Jan Fleuren, G., Houmadi, R., Diss, T., Warren, B., Al Adnani, M., de Goeij, A. P., et al. (2004) · The Journal of Pathology · doi:10.1002/path.1521 · Cited by 237
“Our finding of both BRAF V599E and KRAS in two tumours was therefore surprising, although there has been one previous report in melanocytic lesions [4].”
ResultBarnhill, R. L. (2006) · Modern Pathology · doi:10.1038/modpathol.3800519 · Cited by 235
Zimmer, L., Hillen, U., Livingstone, E., Lacouture, M. E., Busam, K., Carvajal, R. D., Egberts, F., Hauschild, A., Kashani-Sabet, M., Goldinger, S. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.1660 · Cited by 231
Overcoming Immune Evasion in Melanoma
Eddy, K., & Chen, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238984 · Cited by 222
“The genetic abnormalities commonly associated with these two subtypes of cutaneous melanoma are neurofibromin 1 (NF1), NRAS, BRAF non-V600E mutations, or KIT in CSID, while non-CSID is associated with BRAF V600E mutations, suggesting that the non-CSID might originate from nevi (Figure 1) [2,71,72].”
BackgroundKumar, R., Angelini, S., Snellman, E., & Hemminki, K. (2004) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2004.22225.x · Cited by 229
Mitsutake, N., Knauf, J. A., Mitsutake, S., Mesa, C., Zhang, L., & Fagin, J. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3314 · Cited by 228
“However, in melanocytes, oncogenic BRAF is probably not sufficient to induce malignant melanoma because BRAF mutations have also been found in f80% of benign nevi (12).”
BackgroundNormal Human Melanocyte Homeostasis as a Paradigm for Understanding Melanoma
Haass, N. K., & Herlyn, M. (2005) · Journal of Investigative Dermatology Symposium Proceedings · doi:10.1111/j.1087-0024.2005.200407.x · Cited by 227
Damsky, W. E., Rosenbaum, L. E., & Bosenberg, M. (2010) · Cancers · doi:10.3390/cancers3010126 · Cited by 225
“About 80% of human melanocytic nevi contain an activating mutation (V600E) in the BRAF Ser/Thr kinase [20,21].”
BackgroundTwo-Step Senescence-Focused Cancer Therapies
Sieben, C. J., Sturmlechner, I., van de Sluis, B., & van Deursen, J. M. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.04.006 · Cited by 222
Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice
Franco, A. T., Malaguarnera, R., Refetoff, S., Liao, X.-H., Lundsmith, E., Kimura, S., Pritchard, C., Marais, R., Davies, T. F., Weinstein, L. S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015557108 · Cited by 223
“Mutations of BRAF are also found with high frequency in benign nevi and in melanomas (12, 13) and to a lesser extent in lung cancers (14, 15).”
BackgroundMutations of the BRAF Gene in Benign and Malignant Melanocytic Lesions
Yazdi, A. S., Palmedo, G., Flaig, M. J., Puchta, U., Reckwerth, A., Rütten, A., Mentzel, T., Hügel, H., Hantschke, M., Schmid-Wendtner, M.-H., et al. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12559.x · Cited by 221
Quiros, R. M., Ding, H. G., Gattuso, P., Prinz, R. A., & Xu, X. (2005) · Cancer · doi:10.1002/cncr.21073 · Cited by 223
“Clinical studies suggest that BRAF mutation alone is not sufficient to transform melanocytes because BRAF is mutated in approximately 70% of nevi.(23) It is possible that BRAF mutation may cooperate with other genetic alterations to induce thyroid carcinogenesis.”
BackgroundZuidervaart, W., van Nieuwpoort, F., Stark, M., Dijkman, R., Packer, L., Borgstein, A.-M., Pavey, S., van der Velden, P., Out, C., Jager, M. J., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602598 · Cited by 221
“Various other mutations have been described in this exon in melanocytic tumours (V599D (Brose et al, 2002; Davies et al, 2002; Pollock et al, 2003); V599K (Pollock et al, 2003, Uribe et al, 2003); V599R (Pollock et al, 2003); K600E (Brose et al, 2002, Satyamoorthy et al, 2003)).”
BackgroundSelf-citationPathways and therapeutic targets in melanoma
Shtivelman, E., Davies, M. A., Hwu, P., Yang, J., Lotem, M., Oren, M., Flaherty, K. T., & Fisher, D. E. (2014) · Oncotarget · doi:10.18632/oncotarget.1892 · Cited by 217
“Mutations in BRAF alone do not induce melanoma, and the high frequency of BRAF mutations in benign nevi supports this conclusion [6].”
Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues.
Gorden, A., Osman, I., Gai, W., He, D., Huang, W., Davidson, A., Houghton, A. N., BUSAM, K. J., & Polsky, D. (2003) · PubMed · Cited by 212
Bauer, J., Büttner, P., Murali, R., Okamoto, I., Kolaitis, N. A., Landi, M. T., Scolyer, R. A., & Bastian, B. C. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00837.x · Cited by 211
“Activating mutations of the BRAF gene have been reported in the majority of melanocytic nevi and cutaneous melanoma (Davies et al., 2002; Maldonado et al., 2003; Pollock et al., 2003; Yazdi et al., 2003),”
BackgroundIncidence of BRAF Oncogene Mutation and Clinical Relevance for Primary Cutaneous Melanomas
Shinozaki, M., Fujimoto, A., Morton, D. L., & Hoon, D. S. B. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1169-3 · Cited by 212
“Recently, BRAF mutations were reported in 70–80% of congenital, intradermal compound, and dysplastic nevi (5).”
BackgroundAbsence of BRAF and NRAS mutations in uveal melanoma.
Cruz, F., Rubin, B. P., Wilson, D. J., Town, A., Schroeder, A., Haley, A., Bainbridge, T., Heinrich, M. C., & Corless, C. L. (2003) · PubMed · Cited by 208
Model Organisms Facilitate Rare Disease Diagnosis and Therapeutic Research
Wangler, M. F., Yamamoto, S., Chao, H.-T., Posey, J. E., Westerfield, M., Postlethwait, J., Members of the Undiagnosed Diseases Network (UDN), Hieter, P., Boycott, K. M., Campeau, P. M., et al. (2017) · Genetics · doi:10.1534/genetics.117.203067 · Cited by 211
The Transcription Network Regulating Melanocyte Development and Melanoma
Vance, K. W., & Goding, C. R. (2004) · Pigment Cell Research · doi:10.1111/j.1600-0749.2004.00164.x · Cited by 209
BRAF mutations in metastatic melanoma: a possible association with clinical outcome.
Kumar, R., Angelini, S., Czene, K., Sauroja, I., Hahka‐Kemppinen, M., Pyrhönen, S. O., & Hemminki, K. (2003) · PubMed · Cited by 205
Mutations of BRAF and KRAS Precede the Development of Ovarian Serous Borderline Tumors
Ho, C.-L., Kurman, R. J., Dehari, R., Wang, T.-L., & Shih, I.-M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2067 · Cited by 206
“This is supported by the observation that activating mutations in these genes are oncogenic in experimental cell culture systems (19, 27, 28) probably through a constitutive activation of mitogen-activated protein kinase (29, 30).”
BackgroundResultEmuss, V., Garnett, M., Mason, C., The Cancer Genome Project, & Marais, R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1683 · Cited by 207
“Critically, ‘‘oncogenic’’ B-RAF does not induce cancer by itself because a high proportion of common nevi harbor mutations in the B-RAF gene but are not cancerous ( 23 ).”
BackgroundBRAF alterations are associated with complex mutational profiles in malignant melanoma
Daniotti, M., Oggionni, M., Ranzani, T., Vallacchi, V., Campi, V., Di Stasi, D., Torre, G. D., Perrone, F., Luoni, C., Suardi, S., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207780 · Cited by 210
“Other studies confirmed a high frequency of mutations, ranging from 40 to 62%, in melanoma cell lines, primary and metastatic tissues with the notable exception of early melanomas (Brose et al., 2002; Dong et al., 2003; Gorden et al., 2003; Pollock et al., 2003).”
BackgroundMelanoma genetics and the development of rational therapeutics
Chudnovsky, Y., Khavari, P. A., & Adams, A. E. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200524808 · Cited by 204
“org Volume 115 Number 4 April 2005 819 early-stage primary melanomas (65, 81), but others have reported a decreasing mutation frequency in association with more advanced disease (67).”
BackgroundZhuang, D., Mannava, S., Grachtchouk, V, Tang, W.-H., Patil, S., Wawrzyniak, J. A., Berman, A. E., Giordano, T. J., Prochownik, E. V., Soengas, M. S., et al. (2008) · Oncogene · doi:10.1038/onc.2008.258 · Cited by 203
“(Pollock et al., 2003), whereas 81% of benign congenital nevi harbor mutations in the NRAS gene (Bauer et al., 2007).”
BackgroundWiesner, T., Kutzner, H., Cerroni, L., Mihm, M. C., Busam, K. J., & Murali, R. (2016) · Pathology · doi:10.1016/j.pathol.2015.12.007 · Cited by 202
“The vast majority (>80%) show activating hotspot mutations leading to an amino acid exchange at codon 600 of BRAF (BRAF).(12) Congenital naevi arise in utero or post-natally, tend to be significantly larger than common acquired naevi, and harbour often activating NRAS hotspot mutations (~75%), most commonly affecting…”
The journey from melanocytes to melanoma
Centeno, P. P., Pavet, V., & Marais, R. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00565-7 · Cited by 197
Norval, M., Cullen, A. P., de Gruijl, F. R., Longstreth, J., Takizawa, Y., Lucas, R. M., Noonan, F. P., & van der Leun, J. C. (2007) · Photochemical & Photobiological Sciences · doi:10.1039/b700018a · Cited by 199
Genetic Alterations in Signaling Pathways in Melanoma
Haluska, F. G., Tsao, H., Wu, H., Haluska, F. S., Lazar, A., & Goel, V. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2518 · Cited by 198
Targeting oncogenic Raf protein-serine/threonine kinases in human cancers
Roskoski, R. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.08.013 · Cited by 194
Akt3 and Mutant V600EB-Raf Cooperate to Promote Early Melanoma Development
Cheung, M., Sharma, A., Madhunapantula, S. V., & Robertson, G. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5867 · Cited by 196
“Approximately 90% harbor activating B-Raf mutations but never progress into melanomas (12, 14, 15 ).”
BackgroundUse of human tissue to assess the oncogenic activity of melanoma-associated mutations
Chudnovsky, Y., Adams, A. E., Robbins, P. B., Lin, Q., & Khavari, P. A. (2005) · Nature Genetics · doi:10.1038/ng1586 · Cited by 198
“Induction of Ras and Raf can be caused by active N-Ras and B-Raf mutants as well as by gene amplificatio”
BackgroundNumber of Nevi and Early-Life Ambient UV Exposure Are Associated with BRAF-Mutant Melanoma
Thomas, N. E., Edmiston, S. N., Alexander, A., Millikan, R. C., Groben, P. A., Hao, H., Tolbert, D., Berwick, M., Busam, K., Begg, C. B., et al. (2007) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-1038 · Cited by 192
“Nevi, which also frequently contain BRAF mutations (44) and have been found to be increased in number with high early-life UV exposure (45), could be causal intermediates for some melanomas and/or arise in parallel.”
BackgroundFan, T., Jiang, S., Chung, N., Alikhan, A., Ni, C., Lee, C.-C. R., & Hornyak, T. J. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0511 · Cited by 193
“Overexpression of melanoma oncogenes such as BRAFV600E (5) and NRASQ61K (6) provokes oncogene-induced senescence in melanocytes.”
BackgroundInfluentialSchuierer, M. M., Bataille, F., Hagan, S., Kolch, W., & Bosserhoff, A.-K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3861 · Cited by 193
“(7) observed mutations in the BRAF gene not only in samples of malignant melanoma, but also in nevi, suggesting that the BRAF mutation is an early but not sufficient event in malignant melanocyte transformation.”
BackgroundMetabotropic Glutamate Receptor 1 and Glutamate Signaling in Human Melanoma
Namkoong, J., Shin, S.-S., Lee, H. J., Marín, Y. E., Wall, B. A., Goydos, J. S., & Chen, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3665 · Cited by 192
“These findings imply that perhaps most nevi with BRAF mutations may not progress to the next stage in melanoma development [70, 71], and that BRAF may be involved in the initiation rather than the progression of melanoma.”
BackgroundMelanoma: What do all the mutations mean?
Davis, E. J., Johnson, D. B., Sosman, J. A., & Chandra, S. (2018) · Cancer · doi:10.1002/cncr.31345 · Cited by 180
Microarray expression profiling in melanoma reveals a BRAF mutation signature
Pavey, S., Johansson, P., Packer, L., Taylor, J., Stark, M., Pollock, P. M., Walker, G. J., Boyle, G. M., Harper, U., Cozzi, S.-J., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207563 · Cited by 183
Self-citationHocker, T. L., Singh, M. K., & Tsao, H. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.226 · Cited by 189
“Mutations in these two genes occur in a mutually exclusive manner (Pollock et al., 2003; Tsao et al., 2004b), suggesting some degree of functional redundancy between these genetic events.”
BackgroundThe Genomic Landscape of Childhood and Adolescent Melanoma
Lu, C., Zhang, J., Nagahawatte, P., Easton, J., Lee, S., Liu, Z., Ding, L., Wyczalkowski, M. A., Valentine, M., Navid, F., et al. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.425 · Cited by 186
“The oncogenic mutations in BRAF and NRAS or the kinase fusions, however, are insufficient on their own for the development of cancer, as evident by their presence in the nevi of acquired, congenital, or spitzoid types (Pollock et al., 2003; Bauer et al., 2007; Wiesner et al., 2014).”
BackgroundLiu, H., He, Z., von Rütte, T., Yousefi, S., Hunger, R. E., & Simon, H.-U. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005864 · Cited by 188
“Lowering ATG5 expression prevents oncogene-induced senescence in melanocytes It is believed that mutations in BRAF can be the first step in the formation of a melanocytic tumor (30).”
BackgroundLiu, W., Kelly, J. W., Trivett, M., Murray, W. K., Dowling, J. P., Wolfe, R., Mason, G., Magee, J., Angel, C., Dobrovic, A., et al. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700632 · Cited by 188
“Although mutations in BRAF are found in a high proportion of melanocytic nevi (Pollock et al., 2003), the BRAF mutation was associated with neither the total number of melanocytic nevi (P1⁄4 0.”
BackgroundTargeting the ERK Signaling Pathway in Melanoma
Savoia, P., Fava, P., Casoni, F., & Cremona, O. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061483 · Cited by 184
MC 1R, the c AMP pathway, and the response to solar UV: extending the horizon beyond pigmentation
García‐Borrón, J. C., Abdel‐Malek, Z., & Jiménez‐Cervantes, C. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12257 · Cited by 187
“It has been suggested that expression of MC1R variant alleles increases the risk for the somatic activating BRAF mutation BRAFv600E (Landi et al., 2006), that is very commonly found in nevi and melanoma tumors (Pollock et al., 2003).”
BackgroundAssessing cell and organ senescence biomarkers
de Jesus, B. B., & Blasco, M. A. (2012) · Circulation Research · doi:10.1161/circresaha.111.247866 · Cited by 187
Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma
Fedorenko, I. V., Paraiso, K. H. T., & Smalley, K. S. M. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.05.015 · Cited by 186
“Although it has been suggested that the acquisition of the BRAF V600E mutation is an early event in melanoma development, with 80% of all benign nevi shown to be BRAF mutant, the available evidence indicates that mutant BRAF alone cannot initiate melanoma [7, 8].”
BackgroundSala, E., Mologni, L., Truffa, S., Gaetano, C., Bollag, G. E., & Gambacorti-Passerini, C. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2001 · Cited by 188
“(6, 7) and mutations persist from the primary lesion through”
BackgroundJacob, K., Albrecht, S., Sollier, C., Faury, D., Sader, E., Montpetit, A., Serre, D., Hauser, P., Garami, M., Bognar, L., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605179 · Cited by 186
“In keeping with these data, only oncogenic BRAF mutations have been implicated in tumours of epithelial (Rajagopalan et al, 2002) and neuroectodermal origin (Brose et al, 2002; Pollock et al, 2003).”
BackgroundSensi, M., Nicolini, G., Petti, C., Bersani, I., Lozupone, F., Molla, A., Vegetti, C., Nonaka, D., Mortarini, R., Parmiani, G., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209379 · Cited by 183
“Although benign nevi also display BRAFV600E, recent data suggest that such mutation is more frequent in growing nevi that tend to progress to malignancy (Pollock et al., 2003; Loewe et al., 2004).”
BackgroundRole of nuclear factor-κ B in melanoma
Amiri, K. I., & Richmond, A. (2005) · Cancer and Metastasis Reviews · doi:10.1007/s10555-005-1579-7 · Cited by 180
“primary melanomas and, unexpectedly, in 63 of 77 (82%) nevi, suggesting that mutational activation of the RAS/RAF/MAPK pathway in nevi is a critical step in the initiation of melanocytic neoplasia [96].”
Roh, M. R., Eliades, P., Gupta, S., & Tsao, H. (2015) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12412 · Cited by 180
“BRAF mutations were first described in 2003 (Pollock et al., 2003), with 81.”
BackgroundResultInfluentialSwitching on kinases: oncogenic activation of BRAF and the PDGFR family
Dibb, N. J., Dilworth, S. M., & Mol, C. D. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1434 · Cited by 179
Palmieri, G., Capone, M., Ascierto, M. L., Gentilcore, G., Stroncek, D. F., Casula, M., Sini, M. C., Palla, M., Mozzillo, N., & Ascierto, P. A. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-86 · Cited by 177
BRAF Mutations Are Not a Major Event in Post-Chernobyl Childhood Thyroid Carcinomas
Lima, J., Trovisco, V., Soares, P., Máximo, V., Magalhães, J., Salvatore, G., Santoro, M., Bogdanova, T., Tronko, M., Abrosimov, A., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032224 · Cited by 181
Absence of BRAF mutations in UV-protected mucosal melanomas
Edwards, R. H., Ward, M. R., Wu, H., Medina, C. A., Brose, M. S., Volpe, P., Nussen-Lee, S., Haupt, H. M., Martin, A. M., Herlyn, M., et al. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2003.016667 · Cited by 178
Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation
Su, F., Bradley, W. D., Wang, Q., Yang, H., Xu, L., Higgins, B., Kolinsky, K., Packman, K., Kim, M. J., Trunzer, K., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1875 · Cited by 179
“Notably, acquisition of the BRAF V600E mutation seems to be an early event in melanoma development with a high percentage of premalignant melanocytic nevi also found to harbor the mutation (5).”
BackgroundNRAS Mutation Is the Sole Recurrent Somatic Mutation in Large Congenital Melanocytic Nevi
Charbel, C., Fontaine, R. H., Malouf, G. G., Picard, A., Kadlub, N., El-Murr, N., How-Kit, A., Su, X., Coulomb-L'Hermine, A., Tost, J., et al. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.429 · Cited by 178
“, 2011), or selected by histological criteria (Pollock et al., 2003).”
BackgroundThe discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma
Kim, A., & Cohen, M. S. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1201057 · Cited by 169
“Although BRAF is critical in melanoma progression, it was found to be insufficient for melanoma tumorigenesis [30,32].”
BackgroundThe hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation
Bedogni, B., Welford, S. M., Cassarino, D. S., Nickoloff, B. J., Giaccia, A. J., & Powell, M. B. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.11.005 · Cited by 179
“On the other hand, mild hypoxia (1%‐5% O2) has been shown to promote cell proliferation and survival of different cell types (Alaluf et al., 2000; Balin and Pratt, 2002; Studer et al., 2000); to increase the life span of fibroblasts and vascular smooth muscle cells (Minamino et al., 2001; Parrinello et al., 2003 ); an…”
BackgroundInfluentialBRAF as therapeutic target in melanoma
Wellbrock, C., & Hurlstone, A. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.03.019 · Cited by 178
KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression
Oliveira, C., Velho, S., Moutinho, C., Ferreira, A., Preto, A., Domingo, E., Capelinha, A. F., Duval, A., Hamelin, R., Machado, J. C., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1209758 · Cited by 178
“…made in other tumour models, namely activating BRAF mutations have been detected in a high proportion of naevi and benign melanocytic skin lesions (Pollock et al., 2003; Yazdi et al., 2003), although in this specific model, activating mutations of BRAF have also been identified in approximately…”
BackgroundResultBRAF V600E mutation-specific antibody: A review
Ritterhouse, L. L., & Barletta, J. A. (2015) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2015.02.010 · Cited by 172
“In melanoma, BRAF mutation seems to be an early event since many nevi harbor BRAF mutations.(2) While BRAF mutations in primary melanomas have not been found to impact disease-free or overall survival, there is some indication that BRAF mutations in metastatic melanoma impart a decreased survival rate.”
BackgroundMercer, K., Giblett, S., Green, S., Lloyd, D., DaRocha Dias, S., Plumb, M., Marais, R., & Pritchard, C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2211 · Cited by 179
“cancers in vivo , the situation may well be more complex as B-Raf mutations are detected in a high proportion of benign melanocytic lesions (nevi) and premalignant colon polyps in which the cells are thought to be senescent (9, 18, 41, 42).”
Cutaneous Photobiology. The Melanocyte vs. the Sun: Who Will Win the Final Round?
Kadekaro, A. L., Kavanagh, R. J., Wakamatsu, K., Ito, S., Pipitone, M. A., & Abdel‐Malek, Z. A. (2003) · Pigment Cell Research · doi:10.1034/j.1600-0749.2003.00088.x · Cited by 180
Immunohistochemical Detection of the BRAF V600E-mutated Protein in Papillary Thyroid Carcinoma
Koperek, O., Kornauth, C., Capper, D., Berghoff, A. S., Asari, R., Niederle, B., von Deimling, A., Birner, P., & Preusser, M. (2012) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318246b527 · Cited by 175
“This is in concordance to the finding that BRAF mutations, which are common in malignant melanoma, are already evident in noninvasive melanocytic nevi.(28,39) The expression of mutated BRAF was significantly associated with diverse subtypes of PTC.”
ResultA Prospective Study of Telomere Length and the Risk of Skin Cancer
Han, J., Qureshi, A. A., Prescott, J., Guo, Q., Ye, L., Hunter, D. J., & De Vivo, I. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.238 · Cited by 177
“It is believed that activating mutations in BRAF, which are found in 82% of nevi (Pollock et al., 2003), initiate the development of nevi with the onset of rapid proliferation.”
BackgroundThe genomic landscape of cutaneous melanoma
Zhang, T., Dutton‐Regester, K., Brown, K. M., & Hayward, N. K. (2016) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12459 · Cited by 172
“The discovery of frequent BRAF mutations in melanomas (Davies et al., 2002) and melanocytic nevi (Pollock et al., 2003) provided the initial opportunity to search for genetic differences between tumors arising on skin with or without evidence of chronic sun damage (based on the presence or absence…”
BackgroundSelf-citationMelanoma: Molecular Pathogenesis and Therapeutic Management.
Liu, Y., & Sheikh, M. S. (2014) · PubMed · Cited by 212
Mechanisms of mutation formation with long‐wave ultraviolet light (UVA)
Rünger, T. M., & Kappes, U. P. (2008) · Photodermatology, Photoimmunology & Photomedicine · doi:10.1111/j.1600-0781.2008.00319.x · Cited by 171
“A high frequency of T : A ! A : T mutations at one particular site of BRAF has been described in malignant melanomas and melanocytic nevi (53).”
BackgroundNRAS mutant melanoma: biological behavior and future strategies for therapeutic management
Fedorenko, I. V., Gibney, G. T., & Smalley, K. S. M. (2013) · Oncogene · doi:10.1038/onc.2012.453 · Cited by 167
Epigenetic Silencing of Novel Tumor Suppressors in Malignant Melanoma
Muthusamy, V., Duraisamy, S., Bradbury, C. M., Hobbs, C., Curley, D. P., Nelson, B., & Bosenberg, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1274 · Cited by 172
“BRAF is also mutated in f70% of benign melanocytic nevi, suggesting that additional genetic or epigenetic hits are needed for progression to malignancy (6).”
Claudin-1 overexpression in melanoma is regulated by PKC and contributes to melanoma cell motility
Leotlela, P. D., Wade, M. S., Duray, P. H., Rhode, M. J., Brown, H. F., Rosenthal, D. T., Dissanayake, S. K., Earley, R., Indig, F. E., Nickoloff, B. J., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210155 · Cited by 169
“Claudin-1 is highly and aberrantly expressed in melanoma The melanoma tissue microarray, which has been previously described by Pollock et al. (2003), contains samples ranging in stage from nevi to visceral metastases.”
BackgroundSelf-citationJacob, K., Quang-Khuong, D.-A., Jones, D. T. W., Witt, H., Lambert, S., Albrecht, S., Witt, O., Vezina, C., Shirinian, M., Faury, D., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0127 · Cited by 168
“It is unclear to date as to what leads to cellular transformation in this tumor type, as senescence can still be partly triggered in tumor cells (29).”
BackgroundLack of BRAF mutations in uveal melanoma.
Rimoldi, D., Salvi, S., Líénard, D., Lejeune, F. J., Speiser, D. E., Zografos, L., & Cerottini, J. (2003) · PubMed · Cited by 169
Activating MET kinase rearrangements in melanoma and Spitz tumours
Yeh, I., Botton, T., Talevich, E., Shain, A. H., Sparatta, A. J., de la Fouchardiere, A., Mully, T. W., North, J. P., Garrido, M. C., Gagnon, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms8174 · Cited by 167
Analysis of the genome to personalize therapy for melanoma
Davies, M. A., & Samuels, Y. (2010) · Oncogene · doi:10.1038/onc.2010.323 · Cited by 165
“The BRAF V600E mutation is present in up to 80% of benign nevi, which have virtually no malignant potential (Pollock et al., 2003; Yazdi et al., 2003).”
A brief history of melanoma: from mummies to mutations
Rebecca, V. W., Sondak, V. K., & Smalley, K. S. M. (2012) · Melanoma Research · doi:10.1097/cmr.0b013e328351fa4d · Cited by 163
Metadata
- Authors
- Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., Salem, G., Pohida, T., Heenan, P., Duray, P., Kallioniemi, O., Hayward, N. K., Trent, J. M., & Meltzer, P. S.
- Affiliations
- National Institutes of Health (US)
- QIMR Berghofer Medical Research Institute (AU)
- The University of Western Australia (AU)
- Corresponding author
- Meltzer, Paul S.
- ORCID
- Venue
- Nature Genetics
- Published
- 2002-11-25
- Volume
- 33
- Issue
- 1
- Pages
- 19-20
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W1565041471
- Cited by
- 1,730
- References
- 4
- Citations by year
- 2026: 15 · 2025: 24 · 2024: 40 · 2023: 49 · 2022: 46 · 2021: 73 · 2020: 58 · 2019: 73 · 2018: 67 · 2017: 87 · 2016: 79 · 2015: 87 · 2014: 84 · 2013: 104 · 2012: 92
- FWCI
- 25.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Health Sciences › Medicine › Clinical Neurology › Neurofibromatosis and Schwannoma Cases
- Keywords
- BRAF mutation, melanocytic nevi, melanoma, melanoma metastasis, RAS/MAPK pathway, carcinogenesis
- MeSH terms
- Cell Transformation, Neoplastic, DNA Mutational Analysis, Gene Frequency, Humans, Melanoma, Nevus, Signal Transduction, Polymerase Chain Reaction, Genetic Predisposition to Disease, Mutation, Missense, Oncogene Proteins v-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.